title: Epidermal Langerhans cells after allogeneic bone marrow transplantation: depletion by chemotherapy conditioning regimen alone.
abstract: Depletion of Langerhans cells (LC) is known to follow bone marrow transplantation (BMT) and is thought to be mainly related to pretransplant radiation and chemotherapy conditioning regimens. We studied sequential biopsies of clinically normal skin of 22 thalassemic and leukemic patients undergoing allogeneic BMT who had received only chemotherapy (busulfan and cyclophosphamide) as conditioning regimen. LC were identified immunohistochemically using antibodies against CD1a and HLA-DR antigens, and their number expressed per square mm of epidermal vertical section, the latter measured by computerized image analysis. After the preparatory regimen, the number of LC decreased progressively in both leukemic and thalassemic patients. CD1a+ and HLA-DR+ epidermal cells were reduced, respectively, to 68.5% and 64.5% of their original number around Day 2, and to 23.1% and to 18.2% around Day 17. By this time, electron microscopic examination of selected biopsies confirmed the depletion of LC. Variable repopulation was observed between Days 40 and 60. Our results indicate that a conditioning regimen based exclusively on high dose chemotherapy depletes epidermal LC early after BMT, and that such depletion is not related to the development of acute graft-versus-host disease.
authors.affiliation: Clinica Dermatologica, Università di Modena, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Zambruno
authors.forename: G
authors.initials: G
authors.lastname: Girolomoni
authors.forename: V
authors.initials: V
authors.lastname: Manca
authors.forename: M
authors.initials: M
authors.lastname: Andreani
authors.forename: M
authors.initials: M
authors.lastname: Galimberti
authors.forename: G
authors.initials: G
authors.lastname: Lucarelli
authors.forename: A
authors.initials: A
authors.lastname: Giannetti
mesh_terms: D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D018949:Antigens, CD1; D016026:Bone Marrow Transplantation / Q000473:pathology*; D002066:Busulfan / Q000008:administration & dosage; D016923:Cell Death / Q000187:drug effects; D002648:Child; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003713:Dendritic Cells / Q000276:immunology; D004358:Drug Therapy; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007150:Immunohistochemistry; D007801:Langerhans Cells / Q000187:drug effects / Q000473:pathology* / Q000528:radiation effects; D007938:Leukemia / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D008297:Male; D008854:Microscopy, Electron; D008875:Middle Aged; D014184:Transplantation, Homologous; D017086:beta-Thalassemia / Q000188:drug therapy / Q000473:pathology / Q000601:surgery
chemical_list: D015703:Antigens, CD; D018949:Antigens, CD1; D006684:HLA-DR Antigens; D003520:Cyclophosphamide; D002066:Busulfan